US2016250240A1PendingUtilityA1

Methods and compositions for promoting activity of anti-cancer therapies

38
Assignee: ONCOLOGY RES INT LTDPriority: Aug 3, 2006Filed: May 9, 2016Published: Sep 1, 2016
Est. expiryAug 3, 2026(~0 yrs left)· nominal 20-yr term from priority
Inventors:Michael John StoryKenneth Michael Wayte
A61P 35/00A61P 43/00A61P 35/02A61P 9/00A61P 37/00A61P 35/04A61P 27/02A61K 31/513A61P 15/00A61P 11/00A61K 31/506A61K 31/7048A61K 31/437A61K 31/58A61K 31/505A61K 31/568A61K 31/337A61K 45/06A61P 19/04A61P 17/04A61P 13/08A61P 1/00A61K 31/475A61P 17/02A61K 31/704A61P 19/02A61K 33/243
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of inhibiting growth of a cancerous cell, the method including exposing the cancerous cell to doxorubicin and a therapeutically effective amount of prosapogenin A, wherein the cancerous cell is a prostate cancer cell, a breast cancer cell, a colon cell, or a lung cancer cell. 
     
     
         2 . The method of  claim 1 , wherein the method is used to inhibit formation and/or growth of a prostate, breast, colon, or lung tumor in a subject. 
     
     
         3 . The method of  claim 1 , wherein the method is used to treat a prostate, breast, colon, or lung cancer in a subject. 
     
     
         4 . A method of reducing a therapeutic amount of doxorubicin required for treating a cancer in a subject, comprising exposing the subject to a therapeutic amount of prosapogenin A, wherein the prosapogenin A reduces the amount of doxorubicin to which the subject is exposed. 
     
     
         5 . The method of  claim 4 , wherein the method is used to reduce the amount of doxorubicin required for treating a prostate, breast, colon, or lung cancer in a subject. 
     
     
         6 . The method of  claim 1 , wherein the cancerous cell is a prostate cancer cell. 
     
     
         7 . The method of  claim 1 , wherein the cancerous cell is a breast cancer cell. 
     
     
         8 . The method of  claim 1 , wherein the cancerous cell is a colon cancer cell. 
     
     
         9 . The method of  claim 1 , wherein the cancerous cell is a lung cancer cell. 
     
     
         10 . The method of  claim 4 , wherein the cancer is prostate cancer. 
     
     
         11 . The method of  claim 4 , wherein the cancer is breast cancer. 
     
     
         12 . The method of  claim 4 , wherein the cancer is colon cancer. 
     
     
         13 . The method of  claim 4 , wherein the cancer is lung cancer.

Join the waitlist — get patent alerts

Track US2016250240A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.